The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single and multi-hit PIK3CA short variant (SV) genomic alterations (GA) in clinically advanced prostate cancer (CAPC): A genomic landscape study.
 
Carla Miguel
No Relationships to Disclose
 
Gennady Bratslavsky
Employment - AptaMatrix
Leadership - Taurus Diagnostics
Stock and Other Ownership Interests - Ilgen; Respiquest
Consulting or Advisory Role - Johnson & Johnson/Janssen; Novartis
 
Joseph M Jacob
Consulting or Advisory Role - Photocure; Verity Pharmaceuticals
Speakers' Bureau - Urogen pharma
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Dean C. Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Richard S.P. Huang
Employment - Roche/Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Patent on IHC; provisional patent on biomarkers and biomarker methodology.
 
Douglas I. Lin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Submitted patent for HRD calling methodology (Inst)
 
Smruthy Sivakumar
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Ryon Graf
Employment - Epic Sciences; Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Neil Vasan
Leadership - Heligenics
Stock and Other Ownership Interests - Heligenics
Honoraria - General Dynamics Information Technology (GDIT); MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Guidepoint Global; Novartis
Patents, Royalties, Other Intellectual Property - Vasan N, Baselga J. U.S. Patent Number WO2020041684A1: “Biomarkers for Determining Responsiveness of a Cancer to PI3K Inhibitors,” Patent granted February 27, 2020.
Travel, Accommodations, Expenses - Novartis
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine